Device Trial Radar · NCT04905693
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,850
Planned (sponsor's estimate)
Start
Sep 6, 2022
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- United TherapeuticsNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Progressive Pulmonary Fibrosis
Interventions
Inhaled TreprostinilDrug
Inhaled Treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic NebulizerDevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPFTime frame: Baseline to 6 years
Locations
192 sites in 18 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Clinical Trials Center of Middle Tennessee
Franklin, Arizona
Banner University Medical Center-Phoenix
Phoenix, Arizona
189 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.